Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease by Ansari A, Hassan C, Duley J, Marinaki A, Shobowale-Bakre E-M, Seed P, Meenan J, Yim A, Sanderson J in Alimentary pharmacology & therapeutics (2002). PubMed

Abstract

Azathioprine therapy is discontinued in one-third of patients with inflammatory bowel disease because of toxicity or a lack of clinical response. Patients with thiopurine methyltransferase (TPMT) deficiency are intolerant to azathioprine, whilst carriers are at increased risk of side-effects.

[ hide abstract ]

Discussed In Paper

Related In Paper

Variant Annotations

Sign in to see variant annotations.